Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

60.22 -0.15 (-0.25%)

Delayed Quote Updated: 3:59 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

38 39 Next >

Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024

November 05, 2024

From Genentech

Via Business Wire

New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer

October 30, 2024

From Genentech

Via Business Wire

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗

October 30, 2024

Via Benzinga

Biotech Momentum Trades For The Q4 Rally ↗

October 29, 2024

The biotech sector made an interim peak in late February followed by an active summer in very choppy trading.

Via Talk Markets

Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review ↗

October 25, 2024

The major indexes were mixed for the week.

Via Investor's Business Daily

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗

October 23, 2024

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

Via Benzinga

Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations ↗

October 23, 2024

The Swiss drugmaker kept its outlook for the year despite a third-quarter sales miss.

Via Investor's Business Daily

Can Roche Challenge Lilly and Novo in the Weight Loss Market?

October 22, 2024

One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.

Via MarketBeat

Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study

October 18, 2024

From Genentech

Via Business Wire

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗

October 18, 2024

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

Via Investor's Business Daily

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer ↗

October 15, 2024

Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a...

Via Benzinga

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade ↗

October 14, 2024

The analyst is closely watching MariTide, a potential monthly injection to treat obesity.

Via Investor's Business Daily

Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate

October 14, 2024

From Genentech

Via Business Wire

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names ↗

October 11, 2024

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Via Benzinga

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

October 10, 2024

From Genentech

Via Business Wire

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? ↗

October 10, 2024

Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients...

Via Benzinga

Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer ↗

October 08, 2024

Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set...

Via Benzinga

Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year ↗

October 07, 2024

Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared...

Via Benzinga

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains ↗

October 07, 2024

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.

Via The Motley Fool

Topics Artificial Intelligence

Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point? ↗

October 06, 2024

Renowned economist Justin Wolfers highlighted this significant shift on social media platform X, stating, "From the Department of Things Really Are Getting Better: The U.S. obesity rate may have...

Via Benzinga

Week In Review: Regor Sells Two CDK Inhibitors To Genentech For $850 Million ↗

October 05, 2024

Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast cancer. Regor will receive $850 million upfront, a hefty amount for two Phase...

Via Talk Markets

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗

October 04, 2024

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Via Investor's Business Daily

3 Top Stocks That Could Still Rocket Higher in 2024 ↗

October 04, 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

Via The Motley Fool

Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential ↗

September 30, 2024

Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales. The company aims to launch 20 transformative drugs by 2030 while cutting...

Via Benzinga

Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis

September 26, 2024

From Genentech

Via Business Wire

Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points ↗

September 21, 2024

NFLX is among four stocks on the list that's actionable now.

Via Investor's Business Daily

Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows ↗

September 19, 2024

Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in households, marking a global first for an antiviral.

Via Benzinga

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Via Investor's Business Daily

Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses

September 19, 2024

From Genentech

Via Business Wire

1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc) ↗

September 17, 2024

Telemedicine once seemed like it was going to revolutionize healthcare.

Via The Motley Fool

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.